Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.

摘要: Long-term follow-up was obtained on 726 women with advanced ovarian carcinoma (suboptimal stage III and IV) who had received primary chemotherapy two Gynecologic Oncology Group (GOG) protocols between 1976 1982. The first study compared melphalan alone versus plus hexamethylmelamine cyclophosphamide doxorubicin (CA). second evaluated the same CA regimen or without cisplatin. Eligibility for studies same. At last contact, 76 patients were alive. In a multivariate analysis, cell type other than clear mucinous, cisplatin-based treatment, good performance status, younger age, lower stage, clinically nonmeasurable disease, smaller residual tumor volume, absence of ascites favorable characteristics overall survival (P less .05). Second-look laparotomy negative significantly more often among those endometrioid tumors; there no second-look laparotomies mucinous tumors. There 30 suboptimal disease laparotomy; 18 (60%) have experienced recurrence, 13 (43%) died. Although cisplatin treatment beneficial, new treatments are clearly needed.